Junshi Biosciences Announces Toripalimab as Perioperative
SHANGHAI, China, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading...
Source: globenewswire.com
📰 Pr Team News
Page 41 - Pr Team News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Pr Team. Real-time updates on events, politics, business and more.
Junshi Biosciences Announces Acceptance of NDA for VV116 in
SHANGHAI, China, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading...
Source: globenewswire.com
Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC Patients Met Primary Endpoint in Phase 3 Clinical Study
SHANGHAI, China, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated
Source: finanznachrichten.de
CNN Anderson Cooper 360 June 4, 2024 06:49:00
What you make of the court -- the fbi was involved. the idea of dna. their surveillance. what do you make of how this is all unfolding? because initially, people were looking at this particular police department, the pr team and going, why dont we know more? including the families, who were completely, you know, frustrated. and obviously disheartened. they didnt have more. >> really ham fisted handling by the pr folks of the local police department early on. we got conflicting statements, target...
Source: archive.org
Why Elon Musk will fail without a PR Team
Why Elon Musk will fail without a PR Team. From PR Week
Source: prweek.com
Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region
SHANGHAI, China, Dec. 26, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated
Source: finanznachrichten.de
Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region
Investegate announcements from Junshi Biosciences, Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region
United Arab Emirates United States United Kingdom San Francisco Junshi Bioscience Junshi Biosciences
Source: investegate.co.uk
Junshi Biosciences and Hikma Sign Exclusive Licensing
SHANGHAI, China, Dec. 26, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading...
United Arab Emirates United States United Kingdom San Francisco Junshi Bioscience Junshi Biosciences
Source: globenewswire.com
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
- FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA - - Junshi Biosciences and Coherus are actively engaged in ongoing discussions... | December 25, 2022
Source: marketscreener.com
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) GlobeNewswire December 25, 2022 - FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the...
Source: asiaone.com